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Introduction
Sugammadex is a synthetic γ-dextrin derivative that was 
first designed to selectively bind to the steroidal neuro-
muscular blocking agent (NMBA) molecule. Sugammadex 
is now available in over 60 countries, including the Euro-
pean Union, Australia, and Japan. However, it has not yet 
been approved by the Food and Drug Administration in the 
USA due to concerns regarding hypersensitivity. Sugam-
madex has approximately 2.5 times the affinity and selec-
tivity for rocuronium than for vecuronium [1]. However, 
it has no affinity for succinylcholine or benzylisoquinoline 
nonsteroidal muscle relaxants. Thus, reversal by sugam-
madex is an incentive to favor the use of steroidal instead 
of nonsteroidal muscle relaxants. In addition, possible 
rapid reversal is an incentive to propose the use of rocuro-
nium instead of succinylcholine for rapid sequence induc-
tion. For these reasons, use of the combination of rocu-
ronium and sugammadex is becoming popular in some 
countries, including Japan. However, since rocuronium is 
also reportedly associated with a higher rate of IgE-medi-
ated anaphylaxis compared with other steroidal NMBAs 
[2, 3], the probability of the number of cases of hypersen-
sitivity to either drug increasing is high. In this review, we 
seek to highlight the current knowledge regarding the epi-
demiology, mechanisms, clinical presentation, diagnosis, 
and treatment of sugammadex and rocuronium-induced 
anaphylaxis.
Abstract Perioperative anaphylaxis is a life-threatening 
clinical condition that is typically the result of drugs or 
substances used for anesthesia or surgery. The most com-
mon cause of anaphylaxis during anesthesia is reportedly 
neuromuscular blocking agents. Of the many muscle relax-
ants that are clinically available, rocuronium is becom-
ing popular in many countries. Recent studies have dem-
onstrated that succinylcholine (but also rocuronium use) 
is associated with a relatively high rate of IgE-mediated 
anaphylaxis compared with other muscle relaxant agents. 
Sugammadex is widely used for reversal of the effects of 
steroidal neuromuscular blocking agents, such as rocuro-
nium and vecuronium. Confirmed cases of allergic reac-
tions to clinical doses of sugammadex have also been 
recently reported. Given these circumstances, the number 
of cases of hypersensitivity to either sugammadex or rocu-
ronium is likely to increase. Thus, anesthesiologists should 
be familiar with the epidemiology, mechanisms, and clini-
cal presentations of anaphylaxis induced by these drugs. 
In this review, we focus on the diagnosis and treatment 
of anaphylaxis to sugammadex and neuromuscular block-
ing agents. Moreover, we discuss recent studies in this 
field, including the diagnostic utility of flow cytometry and 
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Anaphylaxis is defined as “a serious allergic reaction that 
has a rapid onset and may cause death” [4]. The rate of ana-
phylaxis has increased during the last decade. This increase 
is reportedly as high as 350 % for food-induced anaphy-
laxis and 230 % for nonfood-induced anaphylaxis over the 
last decade [5]. Regarding an immediate allergic hypersen-
sitivity reaction during anesthesia, its incidence rate varies 
between different countries from 1/10,000 to 1/20,000 [6]. 
Between 2009 and 2011, the Japanese Society of Anesthe-
siologists (JSA) conducted a survey on intraoperative com-
plications and reported a total of 237 cases of anaphylaxis 
during anesthesia. The incidence of anaphylaxis based on 
this survey was approximately 1/18,600. This incidence 
included 13 cases of cardiac arrest and one fatal case. Ana-
phylaxis was the most common cause of complications dur-
ing anesthesia that was independent of surgery, anesthetic 
management, and pre-existing comorbidities (data are 
available for JSA members at the following URL; https://
member.anesth.or.jp/App/datura/news2013/pdf/r20130503.
pdf). Hence, although all anesthesiologists may not experi-
ence cases of intraoperative anaphylaxis, it is important for 
them to be aware of the possibility of intraoperative ana-
phylaxis and prepare appropriate drugs and devices for its 
treatment available.
NMBA‑induced anaphylaxis
In France, between 2005 and 2007, the most common 
cause of anaphylaxis during anesthesia was reportedly 
NMBAs (47.4 %). This was followed by latex (20 %) 
and antibiotics (18.1 %) [7]. Succinylcholine (60.6 %) 
and atracurium (19.6 %) were the major causative drugs, 
whereas anaphylaxis to cisatracurium (5.9 %), vecuro-
nium (4.6 %), rocuronium (4.3 %), pancuronium (2.7 %), 
and mivacurium (1.9 %) was also reported [7]. However, 
these results were at the origin of controversy because of 
the difficulty in obtaining definite information concern-
ing the number of patients exposed to each compounds. 
Denominator based on cases actually exposed to each 
agent is hard to obtain because of the difficulties associ-
ated with retrieval of the administration records of many 
thousands of anesthetics [3]. For this reason, relevant 
denominators have usually been estimated from sales data 
or similar metrics, which, however, fail to account for 
confounders such as vials opened but not used, expired 
vials, and repeat administrations or infusions. The varia-
tion in the reported incidence of anaphylaxis to rocuro-
nium, approximately 1:3500–1:445,000 [8, 9], could be 
explained by these biases. To overcome this problem, 
a study with accurate numerators and denominators for 
the calculation was recently conducted at two hospitals 
in Auckland, New Zealand [3]. This study demonstrated 
that the rate of anaphylaxis due to succinylcholine, rocu-
ronium, and atracurium was 1:2079, 1:2498, and 1:7680–
109,000, respectively. Although the risk of allergic 
reactions is not the only drug characteristic that anesthesi-
ologists must take into account when making their clinical 
choice, the likely increased allergic risk associated with 
succinylcholine and rocuronium, and the relatively low 
risk with atracurium must be part of the clinical reasoning 
when considering the use of a NMBA [10]. Cisatracurium 
had the lowest rate of cross-reactivity in patients who had 
previously suffered anaphylaxis to rocuronium and vecu-
ronium [2]. Therefore, anesthesiologists should consider 
the use of cisatracurium as an alternative safe agent, if it 
is available.
Sugammadex‑induced anaphylaxis
Confirmed cases of allergic reactions to clinical doses of 
sugammadex have been recently reported [11, 12]. How-
ever, the number of reports of sugammadex-induced ana-
phylaxis is much less than those for NMBAs [12, 13]. 
To date, the Japanese Society of Anesthesiologists has 
issued a warning about sugammadex-induced anaphy-
lactic shock five times since March 2011. The third one, 
issued in June 2013, included 95 cases of sugammadex-
related allergies that occurred between April 2010 and 
January 2013, although with no incidents of death. In all 
95 cases, the relationship between the reaction and sug-
ammadex was definitively ascertained by the attending 
anesthesiologists. Seventy-eight of the 95 cases fulfilled 
the validation criteria for anaphylaxis. The incidence rate 
of anaphylactic reactions due to sugammadex was esti-
mated as 29 per million cases (1:34,483), based on the 
estimated number of patients (3.09 millions) in whom 
sugammadex was injected during the survey period. The 
alert also pointed out that the incidence rate may have 
been underestimated, because the survey was based on 
spontaneous reports from anesthesiologists and not on 
prospective studies. It is uncertain whether this incidence 
rate is higher in Japan than in other countries, because 
there is no epidemiological survey regarding this so far. 
The other possibility is that these warnings may simply 
reflect a high level of sugammadex usage in Japan. The 
drug company, MSD (Tokyo, Japan), has reported that 
sugammadex usage in Japan in 2010, in terms of mon-
etary value, was more than four times higher than that in 
Spain, the country that showed the second-highest usage 
in the world [11].
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Mechanisms
Anaphylaxis mediated by IgE, IgG, complement, or 
immune complex is defined as immune-mediated anaphy-
laxis, as opposed to non-allergic anaphylaxis (previously 
known as an anaphylactoid reaction) [14]. Allergic reac-
tions to NMBAs are almost exclusively IgE-mediated. Up 
to 75 % of reactions have been reported upon first known 
contact with the NMBA [15, 16]. This suggests a possible 
cross-reaction with IgE antibodies generated by previous 
contact with apparently unrelated chemicals.
Pholcodine hypothesis
This hypothesis originated from the literature that pointed 
out that anaphylaxis to NMBAs was ten times more com-
mon in Norway than in Sweden [17]. The authors sug-
gested that this difference could be due to differences in 
preoperative sensitization due to pholcodine consump-
tion. Indeed, cough syrups containing pholcodine were 
available in Sweden during the 1970s and 1980s, but 
were thereafter withdrawn from the market [18]. Further 
studies conducted to support this hypothesis showed that 
withdrawal of pholcodine from the Norwegian market sig-
nificantly lowered IgE antibodies to pholcodine, morphine, 
and suxamethonium, and even the frequency of suspected 
NMBA anaphylaxis [19]. However, it is unknown whether 
the decrease in the frequency of suspected NMBA anaphy-
laxis was actually a result of lowering of these IgE anti-
bodies. One could argue that an unknown environmental 
factor, other than pholcodine, may have caused this “co-
incidence”. In fact, IgE sensitization to pholcodine and 
morphine was prevalent even in low pholcodine-consum-
ing countries, such as the USA and the Netherlands [20], 
suggesting that IgE sensitization to pholcodine may even 
occur in the absence of pholcodine. In other words, other 
compounds may lead to production of IgE which will 
cross react with pholcodine, NMBAs, and other quaternary 
ammonium-containing compounds. Further epidemiologi-
cal studies to investigate the possible link between phol-
codine exposure and hypersensitivity reactions to NMBAs 
are required.
In contrast to NMBA-mediated anaphylaxis, little is 
known about the mechanism of sugammadex-mediated 
anaphylaxis. It is unknown whether the hypersensitivity 
reactions to sugammadex are IgE-mediated or non-IgE-
mediated due to the lack of sugammadex-specific IgE anti-
bodies. Direct exposure of the patient’s blood to sugamma-
dex may induce non-specific release of various chemical 
mediators, such as histamine and tryptase, from peripheral 
tissue-resident mast cells, although there is no evidence 
that such a phenomenon does actually occur. Indeed, a 
recent study identified a mast cell-specific receptor that is 
responsible for non-allergic anaphylaxis [21]. In 15 cases 
reported in the literatures, none of the patients had a history 
of previous exposure to sugammadex [12]. This evidence 
suggests cross-reactivity between sugammadex and some 
unknown substance. One such possible candidate substance 
is cyclodextrin, present in foods and/or drugs. In fact, the 
average person consumes approximately 4 g of gamma-
cyclodextrins per day in foods [22].
Clinical presentation
In general, anaphylaxis symptoms involve several organ 
systems, including the skin, causing mainly urticarial (80–
90 % of episodes), respiratory tract (70 % of episodes), 
gastrointestinal tract (30–45 % of episodes), cardiovas-
cular (10–45 % of episodes), and central nervous system 
(10–15 % of episodes) [23–26]. Cardiovascular symptoms, 
including hypotension and bradycardia, are more common 
during events occurring in the operating room and are asso-
ciated mainly with the use of muscle NMBAs and latex 
[24]. It is easy for anesthesiologists to recognize changes 
in the hemodynamic conditions of patients (i.e., blood pres-
sure and heart rate) because they are usually monitored in 
the operation room. When a patient develops respiratory 
symptoms, such as bronchospasm, tracheal intubation is 
often required. In some cases of NMBA-induced ana-
phylaxis, symptoms may appear after tracheal intubation. 
However, in case of rapid appearance of symptoms, the 
anesthesiologist may become aware of difficulty in mask 
ventilation. Sugammadex-induced anaphylaxis typically 
presents when the patient is already extubated and is being 
transferred to their hospital bed, the PACU, or ICU, etc. 
[27]. In these cases, emergency re-intubation outside the 
operating room may be required. Skin involvement with 
anaphylaxis may be less frequent in perioperative reac-
tions, making the diagnosis more difficult [28]. In addition 
to being less frequent, skin manifestations are also not eas-
ily recognized because the patient is covered and sedated, 
being unable to report pruritus. Moreover, hoarseness, dys-
phagia, dizziness, and blurred vision, which are warning 
signs of severe anaphylactic reactions, will not be present 
in a sedated patient [28].
Diagnosis
Clinical signs
The first line of evidence for diagnosing anaphylaxis 
includes clinical signs. The National Institute of Allergy 
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and Infectious Diseases (NIAID) and the Food Allergy and 
Anaphylaxis Network (FAAN) proposed clinical criteria 
for diagnosing anaphylaxis [4]. Anaphylaxis is consid-
ered likely if any one of three stipulated criteria is satisfied 
within minutes to hours (Table 1). Depending on the sever-
ity of the reaction, four grades of immediate clinical mani-
festations are described: Grade 1, Cutaneous signs only; 
Grade 2, Measurable but not life-threatening symptoms and 
cutaneous signs, hypotension, tachycardia, and respiratory 
disturbances, such as cough and difficulty in lung inflation; 
Grade 3, Life-threatening symptoms: collapse, tachycardia 
or bradycardia, arrhythmias, bronchospasm; Grade 4, Car-
diac and/or respiratory arrest [29].
It is known that the onset of perioperative anaphy-
laxis usually occurs within 5 min after induction of anes-
thesia [30, 31]. Thus, the timing of appearance of clini-
cal signs sometimes aids in diagnosis. However, agents 
that are administered via other routes, e.g., those applied 
on the skin and mucosa, in the urethra, contact with the 
peritoneum or subcutaneously, may take some time to be 
absorbed and may, therefore, cause reactions after more 
than 15 min [31]. In addition, physicians often need to dis-
criminate between anaphylaxis and other diseases, includ-
ing pulmonary embolism, asthma, and seizure disorders.
Laboratory tests
The second line of evidence for diagnosing anaphylaxis 
is biological assessment, including plasma histamine and 
tryptase measurements [32, 33]. Plasma histamine levels are 
increased for only 15–60 min after symptom onset. In addi-
tion, special handling of the blood sample is required, for 
example, obtaining it through a wide-bore needle, keeping 
it cold at all times, centrifuging it immediately, and freez-
ing the plasma promptly [33, 34]. For isolated mucocutane-
ous (grade 1) reactions, the delay in blood sampling should 
ideally be less than 15 min after the reaction, for grade 2 
reactions sampling should be performed within 30 min, and 
within 2 h for more severe reactions [6]. Plasma or serum 
total tryptase levels, on the other hand, are increased from 
15 min to 3 h after symptom onset, and its measurement 
requires no special handling of the blood sample. Typically, 
anaphylaxis results from mast cell activation, which causes 
release of mast cell tryptase into circulation, although a 
variety of other pathways, including basophil or comple-
ment activation, may combine to produce anaphylaxis. 
These tests have limitations when used to confirm the diag-
nosis of an acute anaphylaxis episode, including suboptimal 
specificity and sensitivity. Thus, the diagnostic accuracy of 
these assays is increased when measurement of histamine 
and tryptase are combined [6, 32]. Measurement of aller-
gen-specific IgE levels in serum is also helpful in patients 
who have experienced anaphylaxis. Specific IgE antibodies 
against succinylcholine (thiocholine ester) can be assayed in 
serum, although the sensitivity is relatively poor (30–60 %). 
Moreover, test kits for serum IgE antibodies against other 
NMBAs but sugammadex are also commercially available 
[35].
Table 1  Clinical criteria for diagnosing anaphylaxis
Modified from Sampson et al. [4]
PEF, peak expiratory flow; BP, blood pressure
* Low systolic blood pressure for children is defined as less than 70 mmHg from 1 month to 1 year, less than [70 mmHg + (2× age)] from 1 to 
10 years, and less than 90 mmHg from 11 to 17 years
Anaphylaxis is highly likely when any one of the following three criteria are fulfilled:
 1. Acute onset of an illness (over minutes to several hours) with involvement of the skin, mucosa, or both (e.g., generalized hives, pruritus or 
flushing, swollen lips-tongue-uvula)
 And at least one of the following
  (a) Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
  (b) Reduced BP or associated symptoms of end-organ dysfunction [e.g., hypotonia (collapse), syncope, incontinence]
 2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (within minutes to several hours):
  (a) Involvement of the skin-mucosal tissue (generalized hives, itch-flush, swollen lips-tongue-uvula)
  (b) Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
  (c) Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence)
  (d) Persistent gastrointestinal symptoms (e.g., cramping abdominal pain, vomiting)
 3. Reduced BP after exposure to a known allergen for that patient (within minutes to several hours):
  (a) Infants and children: low systolic BP (age specific) or greater than 30 % decrease in systolic BPa
  (b) Adults: systolic BP of less than 90 mmHg or greater than 30 % decrease from that person’s baseline
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Skin tests
Skin tests, the third line of evidence, remain the gold 
standard for detection of IgE-mediated reactions, and 
involve exposure of the mast cells in the skin of patients 
who experience anaphylaxis to the suspected allergen [36]. 
The main risk factor for perioperative anaphylaxis to anes-
thetic drugs is a previously uninvestigated severe imme-
diate hypersensitivity reaction during the perioperative 
period [6]. Therefore, an allergological assessment should 
be performed prior to the surgical procedure, if possible. 
Anesthesiologists usually use multiple drugs, including 
hypnotics, NMBAs and opioids, for the induction of anes-
thesia. Thus, it is essential to perform skin tests to several 
agents when NMBAs are suspected as being the causative 
agents of anaphylaxis. Skin prick and/or intradermal tests 
are usually performed 4–6 weeks after the acute reaction 
[6]. A histamine solution (10 mg/ml for skin prick test and 
10 μg/ml for intradermal test) and physiological saline are 
used as positive and negative controls, respectively. The 
sensitivity of the skin prick test seems to be inferior to that 
of the intradermal test for most drugs [6]. Yet, it is pref-
erable to perform skin prick test prior to intradermal test 
for NMBAs and sugammadex, since the results of the skin 
prick test help in determining the first concentration of the 
drug tested with the intradermal test. When the skin prick 
test is negative, intradermal test starts at a 1/1000 dilution 
of the stock solution for NMBAs. The optimal concentra-
tion of both skin prick and intradermal test for specific 
drugs, including NMBAs, has been previously shown [37, 
38]. For example, the maximum concentration of rocuro-
nium for skin prick and intradermal test are 10 mg/ml and 
100 μg/ml, respectively. Prior to proceeding with skin test 
studies on any drug, testing for specificity and optimal test 
concentrations should be undertaken [39]. However, valida-
tion studies of the skin prick and intradermal test for sug-
ammadex currently appear to be lacking, except for one 
recent study, which showed that 1:77 and 1:770 dilutions of 
100 mg/ml sugammadex for intradermal tests did not cause 
skin irritation or false-positive reactions in 11 volunteers, 
suggesting that 1:100 and higher dilutions of sugamma-
dex are not likely to produce false-positive reactions [40]. 
Further studies are still needed to clarify the optimal drug 
concentration during skin prick and intradermal test for 
sugammadex.
Flow cytometry
The flow cytometry-assisted basophil activation test (BAT) 
has been utilized in the diagnosis of immediate-type drug 
hypersensitivity since the early 1990s, when CD63 was 
discovered as a marker of basophil activation [41]. This 
assay has the advantage of not being associated with the 
risk of inducing anaphylaxis during the test [42]. Another 
advantage of the BAT is the relatively high sensitivity and 
specificity for identification of NMBA-induced anaphy-
laxis. In fact, the sensitivity and specificity of BAT for 
rocuronium-induced anaphylaxis were reportedly 91.7 and 
100 %, respectively [43]. The diagnostic utility of BATs in 
immediate type NMBA hypersensitivity was summarized 
in a previous review. According to this review, its specific-
ity was nearly 100 % in most studies, whereas sensitivity 
was in the range of 40–90 % [44]. Given the high speci-
ficity and mediocre sensitivity, the combination of multiple 
methods, such as skin tests and BAT, is likely to improve 
the diagnostic precision for anaphylaxis. So far, there has 
been only one report describing the usefulness of BAT for 
diagnosing sugammadex-induced anaphylaxis [42].
Treatment
Quick recognition of anaphylactic signs and symptoms is 
essential for a favorable prognosis. In this respect, anesthe-
siologists have certain advantages since: (1) hemodynamics 
are usually monitored in patients under general anesthesia, 
and (2) an intravenous line for administration of drugs to 
treat anaphylaxis has already been established. There are 
several guidelines showing how physicians should treat 
a patient who has developed symptoms that are likely to 
be caused by anesthetic drugs during anesthesia [4, 6, 31, 
45] (Fig. 1). Adrenaline is the only drug recommended 
as first-line therapy in all published national anaphylaxis 
guidelines. However, the guidelines do not agree on the ini-
tial dose or route of injection of epinephrine. It should be 
emphasized that treatment must be tailored according to the 
clinical severity, patient’s history, and availability of and 
response to emergency treatment [6].
Primary treatment other than drug therapy is as follows: 
(1) stop administration of the suspected substance; (2) 
call for help and inform the surgeon; (3) apply the Tren-
delenburg position; and (4) maintain the airway and give 
oxygen [31]. Secondary treatment includes administration 
of corticosteroids and antihistamines. Although corticos-
teroids may attenuate the late manifestations of shock [6], 
there is no evidence from high-quality studies for the use 
of steroids in the emergency management of anaphylaxis 
[46]. There is also no consensus among published national 
anaphylaxis guidelines with regard to the use of antihis-
tamines [34]. In cases with bronchospasm without arte-
rial hypotension, an inhaled β2-adrenergic receptor ago-
nist, such as salbutamol or nebulized adrenaline, should 
be administered [6, 31, 47]. On rare occasions, adrenaline 
appears to be ineffective in anaphylaxis. In such cases, 
drugs such as noradrenaline, vasopressin, and glucagon are 
recommended [6, 31, 45].
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Can sugammadex improve rocuronium‑induced 
anaphylaxis?
Several past reports have suggested the possibility of 
improvement in rocuronium-induced anaphylaxis by the 
administration of sugammadex [48–51], based on the spec-
ulation that by encapsulating rocuronium, sugammadex 
might offer a novel treatment to reverse anaphylaxis caused 
by NMBAs. Central to this hypothesis is whether or not 
the allergenic ammonium groups of NMBAs are still able 
to interact with the complementary IgE-antibodies once the 
NMBA is encapsulated [52, 53]. Another issue is whether 
or not encapsulation of rocuronium by sugammadex may 
prevent further mediator release from the mast cells and 
basophils. Some investigators performed laboratory experi-
ments to answer these questions [53–56]. Molecular mod-
els indicated that the determinants of hypersensitivity may 
still be accessible to binding [53, 54]. In addition, CD63 
expression, a marker of basophil activation, could not be 
blocked when sugammadex was added after basophils had 
already been activated by rocuronium [55]. Studies using 
a cutaneous model similarly concluded that sugammadex 
is unlikely to significantly modify the clinical course of 
an established allergic reaction [40]. In contrast to these 
evidences from laboratory settings, a review that summa-
rized 11 cases from seven different countries demonstrated 
recovery from anaphylaxis after sugammadex administra-
tion [13]. Some authors believe that the timing of recov-
ery in relation to the drug’s administration and the rapidity 
and extent of recovery support the efficacy of sugammadex 
[50]. There are several hypotheses to explain the discrep-
ancy between evidences from clinical and laboratory set-
tings, including that administration of sugammadex and 
alleviation of symptoms may have coincided with the ben-
eficial effects of the already-instituted therapy with adrena-
line injection and fluid resuscitation [48]. A recent report 
that retrospectively analyzed 13 cases of presumed rocu-
ronium-induced anaphylaxis concluded that sugammadex 
does not modify the clinical course of a suspected hyper-
sensitivity reaction [57]. The authors raised the hypothesis 
that sugammadex administration on anaphylaxis improves 
cardiac preload after increasing muscle tone by reversing 
neuromuscular blockade. Moreover, they cautioned against 
including sugammadex in anaphylaxis-treatment algo-
rithms [57]. Further studies may be still needed to put an 
end to this debate.
Hypersensivity reacon probably due 
to anesthec agents (See Table 1) 
Severe symptoms? 
(Grade 2 or 3) 
General resuscitave measures 
(Withdrawal of the suspected drug, Inform the surgical 
team and propose an appropriate course of acon, 
administer 100% oxygen) 
Blood sample collecon for tryptase/histamine  
Yes 
For all cases 
Oxygenaon and rapid airway control 
Inject adrenaline in intravenous boluses 
Trendelenburg posion 
Rapid infusion of crystalloid soluons 
No 
(Grade 4) 
Iniate cardiac massage 
Administer a 1 mg bolus of adrenaline 
Instute the usual resuscitaon measures for 
failing circulaon 
Careful observaon in ICU or recovery unit 
Treatment of hypersensivity reacons under 
anesthesia 
Postoperave evaluaon  
Determinaon of the causave agent and 
strategy for subsequent anesthesia  
Consider either local-regional anesthesia or 
general anesthesia without NMBAs 
Test all NMBAs (intradermal test) 
Consider: Timing of appearance of allergic symptoms 
Past history of hypersensivity reacon 
Results of measurement of serum tryptase/histamine 
Is it likely to be 
anaphylaxis? 
Yes No 
Consider another diagnosis 
Test the agents used during previous anesthesia procedure 
(Prick and/or intradermal tests)  
In vitro assays including basophil acvaon test 




Avoid causave agent in subsequent anesthesia 
Fig. 1  Anesthetic management of patients with perioperative anaphylaxis (diagnosis, treatment, and strategy for subsequent anesthesia). Modi-
fied from Mertes et al. [6]
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Anesthetic management of a patient with a history 
of anaphylaxis during previous surgery
As patients with NMBA anaphylaxis frequently cross-react 
with other NMBAs, alternative anesthetic techniques that do 
not require the use of muscle relaxants should be considered 
for subsequent operations. If this is difficult, alternative safe 
NMBAs should be used. Rocuronium has an intermediate 
risk of anaphylaxis, as its rate of cross-reactivity is less than 
that of succinylcholine but greater than that of vecuronium 
[58] (Fig. 1). A study on the cross-reactivity between NMBAs 
demonstrated that patients with rocuronium anaphylaxis are 
most likely to also test positive for succinylcholine (44 %) 
and vecuronium (40 %) during skin tests, while pancuronium 
and atracurium were also frequent cross-reactors (19 and 
20 %, respectively) [2]. Cisatracurium was the least likely to 
cross-react, at 5 % [2]. Given the possibility of false-negative 
reactions in skin tests, avoidance of the use of all NMBAs in 
patients with a history of anaphylaxis to rocuronium seems 
prudent. Indeed, there are several case reports describing 
patients in whom false-negative skin tests led to a second 
severe anaphylactic reaction to another NMBA [59, 60]. If the 
surgical procedure requires muscle relaxation, the anesthesiol-
ogist should assess the balance of risks. In the case of sugam-
madex-induced anaphylaxis, it is much easier to find an alter-
native safe drug, such as neostigmine, which is the classical 
reversal agent for NMBAs. In many aspects, sugammadex is 
superior to classical reversal agents. However, the demerits of 
neostigmine are negligible compared to the risk of anaphylaxis 
with sugammadex. Besides avoiding the anaphylaxis-inducing 
agent, prudent anesthetic management, including preparation 
of therapeutic agents and careful monitoring, is required for 
patients with a past history of perioperative anaphylaxis.
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